Veracyte announces new data from multiple studies in thyroid cancer diagnosis
Veracyte announced that new findings from six studies reinforcing the "real world" performance of the next-generation Afirma Genomic Sequencing Classifier and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th Annual Meeting of the American Thyroid Association. Researchers from leading institutions presented posters showing that use of the Afirma GSC at their respective centers significantly increased the identification of benign thyroid nodules among those deemed indeterminate - not clearly benign or malignant - following cytopathology review, compared to the original Afirma test. The Ohio State University - Researchers compared results of 113 indeterminate samples that were tested with the Afirma GSC to those of 403 samples using the earlier version of the test. The Afirma GSC identified 74.1% of the nodules as benign, compared to 48.4% with the GEC, an increase of 53%. The overall surgery rate among all patients who underwent genomic testing decreased by more than half - from 42.2% with the GEC to 20.2% with the GSC. Cleveland Clinic - Comparing results of 46 samples tested with the Afirma GSC between July 2017 and December 2017 with 182 samples tested with the original test between December 2011 and July 2017, researchers found that the GSC identified 67.4% as benign, compared to 41.8% with the GEC - an increase of 61%. The overall surgery rate for nodules tested with the GSC was 32.6%, compared to 47.3% with the original test, a decrease of 31%. Brigham and Women's Hospital - Researchers evaluated results for 583 thyroid nodules tested with either the Afirma GSC or GEC between 2011 and 2018. They found that the Afirma GSC identified 64.9% of nodules as benign, compared to 47.9% with the GEC, an increase of 35%. Additionally, in two oral presentations, researchers shared the first "real world" Afirma Xpression Atlas data, providing insights into the distribution of a wide range of gene variants and fusions across key categories of indeterminate thyroid nodules and Afirma GSC results.